Search research articles
Contact Us
Filters
Showing results (141-150 of 155) with videos related to
Page
of 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R J Motzer, C Porta, M Eto, et al.
ESMO Open
|
September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]
T K Choueiri, J Larkin, S Pal, et al.
ESMO Open
|
April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
T K Choueiri, J Larkin, S Pal, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
R S Matulewicz, F Baky, N Liso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
T K Choueiri, T M Kuzel, S S Tykodi, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 155) with videos related to
Sort By:
Page
of 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R J Motzer, C Porta, M Eto, et al.
ESMO Open
|
September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]
T K Choueiri, J Larkin, S Pal, et al.
ESMO Open
|
April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
T K Choueiri, J Larkin, S Pal, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
R S Matulewicz, F Baky, N Liso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
T K Choueiri, T M Kuzel, S S Tykodi, et al.
Page
of 16